Overview

Phase I, Open Label, Single Center Safety Study of [F-18]FLT

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
This is a ten subject, phase 1 study. The purpose of the Phase 1 study is to demonstrate drug safety in a target group of subjects with high grade brain cancer. This population represents a potential clinical population that may benefit from this PET imaging tracer. The study will also begin collection of baseline imaging data and allow us to gain information to improve design and conduct of future trials.
Phase:
Phase 1
Details
Lead Sponsor:
Siemens Molecular Imaging
Treatments:
Alovudine